Recentin

Recentin Uses, Dosage, Side Effects, Food Interaction and all others data.

The novel indole-ether quinazoline Recentin is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Recentin is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors. The preclinical profile of Recentin indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor. Phase I data indicate that Recentin is generally well tolerated, with the most common dose related adverse events being diarrhoea, hoarseness, headache and hypertension.

Trade Name Recentin
Generic Cediranib
Cediranib Other Names Cediranib
Type
Formula C25H27FN4O3
Weight Average: 450.5053
Monoisotopic: 450.206718955
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Recentin
Recentin

Uses

For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

How Recentin works

Recentin inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK). By forming a blockade at the VEGF receptors, Recentin limits the growth of new blood vessels, which are essential to supporting tumor growth. Thus, lacking sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth and potentially improving the efficacy of other treatments. Preclinical evidence indicated that the drug had a high affinity at these sites, and was well tolerated and efficacious in animal studies.

Elimination Route

Available following oral administration.

Half Life

12 to 35 hours

Innovators Monograph

You find simplified version here Recentin

*** Taking medicines without doctor's advice can cause long-term problems.
Share